GTBP

GT Biopharma Inc. (GTBP) | Rumor.io

GT Biopharma

GTBP

Attention (50-day avg)0%

Attention rank (50-day avg)#2,015

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.05

Market capitalization12.3M

Earnings per share128.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-28.4M

Social

What share of all stock conversation is about GTBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 15

GT Biopharma has secured FDA IND clearance for GTB-5550 in multiple myeloma, opening the door to a potential third Phase 1 trial for its B7-H3-targeted NK-cell engager.
The company has announced a potential new indication for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, for multiple myeloma, and has also announced a first patient dosed in a Phase 1 trial of a B7-H3-targeted NK cell.
GT Biopharma has secured a private placement of Series M 10% Convertible Preferred Stock, creating potential equity dilution and governance actions, and has also announced a 1:25 stock split, which has resulted in a small float and accumulation in the stock.

Generated by AI

Sentiment

Of the messages about GTBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.03% +6.31
Bearish	—	—	0% 0	7.97% -6.31

Bullish· Jan 15

$GTBP is advancing a focused biopharma pipeline with disciplined clinical execution and strategic partnerships, offering targeted exposure to meaningful catalysts in high-growth therapeutic markets.
The stock has reclaimed its moving average with high conviction, basing out after a Wave 5 flush, and if support holds, it could be looking at a major trend pivot.
Shorts are likely to get slaughtered as the stock is poised for a big move, with some traders predicting a target price of $0.90 and others calling for a buy signal.

Bearish· Feb 25

The company may be struggling financially, as evidenced by its need for cash and the decision to withdraw and refile an offering.
The stock's price action suggests it may be manipulated, with a possible orchestrated pump to sell into.
The stock's technicals are bearish, with a broken bullish pennant and a lack of volume supporting the current price.

Generated by AI

Topics

Of the messages about GTBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	98.13%
Analysts	—	—	0%	0.12%
Controversies	—	—	0%	0.75%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1%

Announcements· Jan 15

GT Biopharma, Inc. ($GTBP) submitted an IND application to the FDA in December 2025 for its GTB-5550 TriKE solid tumor therapy.
The company plans to conduct a Phase 1 basket trial in 2026 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for B7-H3-expressing solid tumor cancers.
GT Biopharma has a preliminary unaudited cash balance of approximately $7 million as of December 31, 2025, which is expected to be sufficient until Q3 2026.

Technical Analysis· May 20

The author notes a short and long position in $GTBP, breaking out at 5.50 and then shorting at the top formation.
A potential halt at 9.29 is discussed, with a cup and handle formation identified and a resistance level at 9.29.
The author warns of a potential drop in $GTBP, suggesting a strong break or a price level of 8.3 to confirm the move to 9 resistance.

Generated by AI

Community

Of the messages about GTBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	12.87%	6.48%
Newcomers	—	—	87.13%	93.52%

Sep 15

GT Biopharma has achieved a development milestone for a human trial of its novel blood cancer therapy, a significant step towards its immuno-oncology pipeline.
The company has announced the first patient dosed in a Phase 1 trial of its B7-H3-targeted NK cell engager, a key milestone in its clinical-stage biopharma journey.
GT Biopharma has secured FDA IND clearance for GTB-5550 in multiple myeloma, potentially paving the way for a third Phase 1 trial of its B7-H3-targeted NK-cell engager, a significant step forward for the company.

Generated by AI

News

GT Biopharma Regains Nasdaq Minimum Bid Compliance

Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.

3d agoThe Globe and Mail

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

14d agoYahoo Finance

GT Biopharma announces $7.45 million private placement of preferred stock and warrants

14d agoInvesting.com

GT Biopharma receives FDA clearance for myeloma trial

14d agoInvesting.com

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway

15d agoYahoo Finance

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma, Inc. (NASDAQ:GTBP) on Tuesday secured IND clearance from the U.S. Food and Drug Administration (FDA) to evaluate its novel therapeutic candidate, GTB-5550, in treating multiple myeloma. Multiple myeloma is a rare type of blood cancer that develops in the plasma cells, which are a type of white blood cell found in the bone marrow. The trial initiation is contingent upon timing and receipt of non-dilutive grant funding. Cash balance as of September 15 is approximately $11 million, an

15d agoYahoo Finance UK

Also Discussed

Investors talking about GTBP also mention

#	Name	Attention
1	LIPO - Lipella Pharmaceuticals Inc.	——
2	Bone Biologics CorpBBLG	0%+0
3	Werewolf Therapeutics Inc.HOWL	0%0
4	GRIL - Muscle Maker, Inc.	——
5	KMPH - KemPharm, Inc.	——
6	MDVL - MedAvail Holdings, Inc.	——
7	Trevi Therapeutics, Inc.TRVI	0%new
8	Innovate Corp.VATE	0%0
9	GLDN - Nicholas Gold Income ETF	——
10	Sunshine Biopharma Inc.SBFM	0%0

GT Biopharma Inc.

Healthcare
Biotechnology

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic malignancies, solid tumors, and autoimmune conditions. Its current pipeline includes programs such as GTB-3650, GTB-5550, and GTB-7550, which reflect the company’s emphasis on targeted biologic therapies that work through immune cell engagement rather than traditional chemotherapy approaches. GT Biopharma’s work is centered on advancing novel cancer and immune-modulating treatments through product development, clinical research, and commercialization efforts in the biotechnology market.

Website

Location

315 Montgomery Street

San Francisco, CA, 94104

United States

Social

What share of all stock conversation is about GTBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 15

GT Biopharma has secured FDA IND clearance for GTB-5550 in multiple myeloma, opening the door to a potential third Phase 1 trial for its B7-H3-targeted NK-cell engager.
The company has announced a potential new indication for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, for multiple myeloma, and has also announced a first patient dosed in a Phase 1 trial of a B7-H3-targeted NK cell.
GT Biopharma has secured a private placement of Series M 10% Convertible Preferred Stock, creating potential equity dilution and governance actions, and has also announced a 1:25 stock split, which has resulted in a small float and accumulation in the stock.

Generated by AI

Sentiment

Of the messages about GTBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.03% +6.31
Bearish	—	—	0% 0	7.97% -6.31

Bullish· Jan 15

$GTBP is advancing a focused biopharma pipeline with disciplined clinical execution and strategic partnerships, offering targeted exposure to meaningful catalysts in high-growth therapeutic markets.
The stock has reclaimed its moving average with high conviction, basing out after a Wave 5 flush, and if support holds, it could be looking at a major trend pivot.
Shorts are likely to get slaughtered as the stock is poised for a big move, with some traders predicting a target price of $0.90 and others calling for a buy signal.

Bearish· Feb 25

The company may be struggling financially, as evidenced by its need for cash and the decision to withdraw and refile an offering.
The stock's price action suggests it may be manipulated, with a possible orchestrated pump to sell into.
The stock's technicals are bearish, with a broken bullish pennant and a lack of volume supporting the current price.

Generated by AI

Topics

Of the messages about GTBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	98.13%
Analysts	—	—	0%	0.12%
Controversies	—	—	0%	0.75%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1%

Announcements· Jan 15

GT Biopharma, Inc. ($GTBP) submitted an IND application to the FDA in December 2025 for its GTB-5550 TriKE solid tumor therapy.
The company plans to conduct a Phase 1 basket trial in 2026 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for B7-H3-expressing solid tumor cancers.
GT Biopharma has a preliminary unaudited cash balance of approximately $7 million as of December 31, 2025, which is expected to be sufficient until Q3 2026.

Technical Analysis· May 20

The author notes a short and long position in $GTBP, breaking out at 5.50 and then shorting at the top formation.
A potential halt at 9.29 is discussed, with a cup and handle formation identified and a resistance level at 9.29.
The author warns of a potential drop in $GTBP, suggesting a strong break or a price level of 8.3 to confirm the move to 9 resistance.

Generated by AI

Community

Of the messages about GTBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	12.87%	6.48%
Newcomers	—	—	87.13%	93.52%

Sep 15

GT Biopharma has achieved a development milestone for a human trial of its novel blood cancer therapy, a significant step towards its immuno-oncology pipeline.
The company has announced the first patient dosed in a Phase 1 trial of its B7-H3-targeted NK cell engager, a key milestone in its clinical-stage biopharma journey.
GT Biopharma has secured FDA IND clearance for GTB-5550 in multiple myeloma, potentially paving the way for a third Phase 1 trial of its B7-H3-targeted NK-cell engager, a significant step forward for the company.

Generated by AI

GT Biopharma

Social

Sep 15

Bullish· Jan 15

Bearish· Feb 25

Announcements· Jan 15

Technical Analysis· May 20

Sep 15

GT Biopharma Regains Nasdaq Minimum Bid Compliance

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma announces $7.45 million private placement of preferred stock and warrants

GT Biopharma receives FDA clearance for myeloma trial

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

Also Discussed

GT Biopharma Inc.

Company Information

Location

GT Biopharma Regains Nasdaq Minimum Bid Compliance

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma announces $7.45 million private placement of preferred stock and warrants

GT Biopharma receives FDA clearance for myeloma trial

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

Also Discussed

Social

Sep 15

Bullish· Jan 15

Bearish· Feb 25

Announcements· Jan 15

Technical Analysis· May 20

Sep 15